Pacira BioSciences Q4 Earnings Call Highlights
Pacira BioSciences (NASDAQ:PCRX) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight what CEO Frank Lee described as a “transformative year,” pointing to renewed EXPAREL volume momentum, strengthened intellectual property protection, expanded reimbursement coverage, and a pipeline entering a “data-rich” period. Lee said the company finished 2025 with $726 million in revenue [...]